Metabolomics reveals differences between three daidzein metabolizing phenotypes in adults with cardiometabolic risk factors.

Autor: Reverri EJ; Department of Nutrition, University of California, Davis, CA, USA., Slupsky CM; Department of Nutrition, University of California, Davis, CA, USA.; Department of Food Science and Technology, University of California, Davis, CA, USA., Mishchuk DO; Department of Food Science and Technology, University of California, Davis, CA, USA., Steinberg FM; Department of Nutrition, University of California, Davis, CA, USA.
Jazyk: angličtina
Zdroj: Molecular nutrition & food research [Mol Nutr Food Res] 2017 Jan; Vol. 61 (1). Date of Electronic Publication: 2016 Aug 03.
DOI: 10.1002/mnfr.201600132
Abstrakt: Scope: The soy isoflavone, daidzein, is metabolized by gut microbiota to O-desmethylangolensin (ODMA) and/or equol. Producing equol is postulated as a contributing factor for the beneficial effects of soy.
Methods and Results: This randomized, controlled, cross-over design used an untargeted metabolomic approach to assess the metabolic profile of different daidzein metabolizers. Adults (n = 17) with cardiometabolic risk factors received soy nuts or control food for 4 weeks, separated by a 2-week washout. No significant differences were detected pre- and postintervention and between interventions. Examination of the ability to metabolize daidzein revealed three groups: ODMA only producers (n = 4), equol + ODMA producers (n = 8), and nonproducers (n = 5). Analysis of the serum metabolome revealed nonproducers could be distinguished from ODMA-only and equol + ODMA producers. Differences between these phenotypes were related to obesity and metabolic risk (methionine, asparagine, and trimethylamine) with equol + ODMA producers having lower concentrations, yet paradoxically higher pro-inflammatory cytokines. In urine, nonproducers clustered with ODMA producers and were distinct from equol + ODMA producers. Urinary metabolite profiles revealed significantly higher excretion of fumarate and 2-oxoglutarate, as well as pyroglutamate, alanine, and the gut microbial metabolite dimethylamine in equol + ODMA producers.
Conclusion: These results emphasize that the serum and urine metabolomes are distinct based on the ability to metabolize isoflavones.
(© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
Databáze: MEDLINE
Externí odkaz: